June 2012 Clinical Laboratory News: Volume 38, Number 6

CLN Banner Logo

COVER STORIES

Screening Tests in the Age of Austerity
Who Will Define Their Value?
By Bill Malone

With renewed controversy about the value of screening tests like PSA, it seems clinical labs will increasingly face the assumption that overuse and wasteful testing is rampant. However, the current evidence on overuse of lab testing is slim. And even where evidence does exist, a clear picture has yet to form of how physicians and patients could make better decisions—especially about screening tests.

MouseOnline Extra
Low-Value Scenarios for Lab Tests
Urine Drug Monitoring in Pain Therapy
What’s the Best Testing Strategy?
By Genna Rollins

Which patients on long-term pain therapy should undergo urine drug monitoring, and by what methods and how often should they be tested? An expert panel recently made recommendations about these questions which they hope will provide a framework for standardizing urine drug monitoring in the treatment of chronic pain, and serve as a catalyst to advance research in this field.

MouseOnline Extra
Universal Precautions in Pain Management

SERIES ARTICLE

Testosterone
An Overview of CDC’s Standardization Initiative
By Hubert W. Vesper, PhD, and Julianne Cook Botelho, PhD

A number of concerns exist about the reliability of testosterone assays, especially when it comes to measuring free testosterone with homogenous assays. CDC, with broad input from various professional societies, is leading the Hormone Standardization Program with an initial focus on standardizing testosterone measurements, a initiative that will help labs produce more accurate results.

NEWS BRIEF

Report Details U.S. Population Nutrition Status

INSIDE

2012 AACC Annual Meeting Preview

Find out more about the 2012 Annual Meeting in our preview, including a Q&A with the organizing committee chair, Paolo Fortina, MD, PhD, a look at the plenary speakers, exhibitors at the Clinical Lab Expo, and special AACC Division events.

Rethinking ß-Cell Function After Type 1 Diabetes Onset
Ultrasensitive Assay Detects C-Peptide Decades Post-Diagnosis
By Genna Rollins

New research suggests that β-Cell function may persist decades after diagnosis of type 1 diabetes.

PROFILES

Regulatory Profiles
Industry Profiles
Diagnostic Profiles
News from the FDA

Page Access:

Next Month


At-Home Rapid HIV Testing

Circulating Endothelial Cells and Acute MI